Verition Fund Management LLC Buys 25,440 Shares of The Cooper Companies, Inc. (NASDAQ:COO)

Verition Fund Management LLC increased its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 153.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,053 shares of the medical device company’s stock after purchasing an additional 25,440 shares during the quarter. Verition Fund Management LLC’s holdings in Cooper Companies were worth $4,640,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of COO. Kayne Anderson Rudnick Investment Management LLC boosted its stake in Cooper Companies by 3.0% in the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 7,820,590 shares of the medical device company’s stock valued at $682,738,000 after acquiring an additional 231,155 shares during the last quarter. Victory Capital Management Inc. boosted its stake in Cooper Companies by 23.0% in the third quarter. Victory Capital Management Inc. now owns 3,950,119 shares of the medical device company’s stock valued at $435,856,000 after acquiring an additional 737,726 shares during the last quarter. Impax Asset Management Group plc boosted its stake in Cooper Companies by 31.0% in the second quarter. Impax Asset Management Group plc now owns 2,359,798 shares of the medical device company’s stock valued at $205,511,000 after acquiring an additional 558,886 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Cooper Companies by 11.9% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,818,610 shares of the medical device company’s stock valued at $200,665,000 after acquiring an additional 194,118 shares during the last quarter. Finally, Champlain Investment Partners LLC boosted its stake in Cooper Companies by 8.0% in the third quarter. Champlain Investment Partners LLC now owns 1,818,345 shares of the medical device company’s stock valued at $200,636,000 after acquiring an additional 134,875 shares during the last quarter. 24.39% of the stock is owned by institutional investors.

Insider Activity at Cooper Companies

In related news, CFO Brian G. Andrews sold 24,788 shares of the firm’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $105.90, for a total value of $2,625,049.20. Following the completion of the transaction, the chief financial officer now owns 6,614 shares of the company’s stock, valued at approximately $700,422.60. This trade represents a 78.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Albert G. White III sold 114,992 shares of the firm’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $110.53, for a total transaction of $12,710,065.76. Following the completion of the transaction, the chief executive officer now directly owns 165,273 shares of the company’s stock, valued at approximately $18,267,624.69. This trade represents a 41.03 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 141,381 shares of company stock valued at $15,508,071. Corporate insiders own 2.00% of the company’s stock.

Wall Street Analysts Forecast Growth

COO has been the topic of a number of recent research reports. Robert W. Baird raised their price objective on shares of Cooper Companies from $118.00 to $125.00 and gave the company an “outperform” rating in a research note on Thursday, August 29th. StockNews.com upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating in a report on Tuesday. Stifel Nicolaus reiterated a “buy” rating and issued a $115.00 target price (up from $110.00) on shares of Cooper Companies in a report on Thursday, August 29th. Piper Sandler increased their target price on shares of Cooper Companies from $115.00 to $120.00 and gave the stock an “overweight” rating in a report on Thursday, August 29th. Finally, Wells Fargo & Company increased their target price on shares of Cooper Companies from $110.00 to $115.00 and gave the stock an “overweight” rating in a report on Thursday, August 29th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $117.00.

Cooper Companies Trading Up 0.3 %

Shares of NASDAQ:COO opened at $103.29 on Wednesday. The Cooper Companies, Inc. has a 12 month low of $82.55 and a 12 month high of $112.38. The company has a quick ratio of 1.18, a current ratio of 1.99 and a debt-to-equity ratio of 0.33. The company’s fifty day simple moving average is $105.04 and its 200 day simple moving average is $98.66. The firm has a market cap of $20.57 billion, a price-to-earnings ratio of 57.54, a PEG ratio of 2.23 and a beta of 0.97.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.